Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 7/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 6/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL934369 | 0.77 | CDK2 (0.42) | CCNT1BRD4EHMT2 | |
| SCHEMBL934391 | 0.76 | KCNH2 (0.38) | CCNT1CDK9KCNH2 | |
| SCHEMBL1044968 | 0.74 | CDC7 (0.61) | CCNT1CDK9AURKBJAK2JAK3 | |
| SCHEMBL935451 | 0.71 | IDO1 (0.39) | — | |
| SCHEMBL19377884 | 0.71 | CCNT1 (0.43) | CCNT1BRD4ATAD2CDK9EHMT2 | |
| SCHEMBL21604522 | 0.69 | BRD4 (0.50) | CCNT1BRD4ATAD2EHMT2AURKB | |
| SCHEMBL22792032 | 0.68 | EHMT2 (0.45) | CCNT1BRD4ATAD2EHMT2AURKB | |
| SCHEMBL30085803 | 0.68 | SYK (0.48) | CCNT1AURKBSYKKCNH2 | |
| SCHEMBL28894892 | 0.68 | SYK (0.48) | CCNT1AURKBSYKKCNH2 | |
| SCHEMBL530604 | 0.68 | CHEK1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454262-B1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | ABBOTT LAB (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8383624-B2 | Pyrrolopyrazine inhibitors of kinases | ABBOTT LABORATORIES (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2454262-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | Abbott Laboratories (US) | 2012-05-23 | — | — | EP | disclosed |
| CN-102471345-A | Pyrrolopyrazine inhibitors of kinases | ABBOTT LAB | 2012-05-23 | — | — | CN | disclosed |
| US-20110015172-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | disclosed |
| WO-2011008830-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015172-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | CDC7, CDK7, CDK17 | CCNT1 190/4885BRD4 1408/4885ATAD2 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.